Abstract
Summary
Two valeric acid derivatives 4-[2-carboxyethyl]-7-methyl-5-oxoindan-1β-yl valeric acid [compound X] and 4-(decahydro-6-methyl-3-oxo-cyclopenta [f] quinolin-7β-yl) valeric acid [compound Y]) and clofibrate (ethyl p-chlorophenoxyisobutyrate) have been studied for their effects on cholesterol absorption, 7α-hydroxylation and oxidation, hepatic lipogenesis, and serum and liver lipid levels in rats. All three test compounds were fed (0.3% of diet) for 2 wk.
Compound Y was similar to clofibrate in its effects. Compound Y administration resulted in decreased hepatic synthesis of cholesterol and fatty acids, increased oxidation of [26-14C] cholesterol to 14CO2 and increased 7α-hydroxylation of cholesterol. Compound X had no significant effect on any of these parameters.
Clofibrate exhibited a hypocholesteremic effect and clofibrate and compound Y were hepatomegalic. Cholesterol absorption was decreased by clofibrate but not by the two valeric acid derivatives.
Get full access to this article
View all access options for this article.